The Efficacy and Safety of Atezolizumab and Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma

초록

Background & Aims: Atezolizumab-bevacizumab combination therapy has been approved for first-line systemic chemotherapy in advanced hepatocellular carcinoma. Real-world retrospective analysis was performed to evaluate the effectiveness and safety of the chemotherapy. Methods: A single-center, retrospective cohort study was performed. Between January 2020 and July 2023, patients with advanced hepatocellular carcinoma who received atezolizumab-bevacizumab systemic therapy were enrolled. Response to the therapy was assessed with mRECIST criteria. Evaluation of first radiologic response, best overall response, progression-free survival, and overall survival was done. Safety data were collected. Also, prognostic factors for first radiologic response, progression-free survival, and overall survival were also assessed. Results: A total of 70 patients were investigated. Baseline characteristics showed a median age of 63 years, male dominance (89%), and viral etiology (84%). Four patients achieved complete response and 19 reached partial response when evaluated by best overall response. Response duration was 4.7 months (range 1.5-25.5). Median progression-free survival was 4.1 months (95% CI, 3.7-6.7), and median overall survival was 24.6 months (95% CI, 11.6-). Age and tumor extent of over 50% of the liver was predictive of progression-free survival (p=0.009 and p=0.007, respectively) Tumor extent of over 50% of the liver and ALBI score were predictive of overall survival (p=0.025 and p=0.004, respectively). Conclusion: Atezolizumab-bevacizumab therapy showed valuable outcomes and tolerable safety profiles in real-world advanced HCC patients. The outcome and safety results were comparable to previous studies.